EGFL7 Recombinant Protein | EGFL recombinant protein

mouse EGFL7 Recombinant

Cat. Num. AAA553330

• Purity: >90%, as determined by SDS-PAGE
• Synonyms: EGFL7; mouse EGFL7 Recombinant; ve-statin; EGFL recombinant protein

• Host: Insect Cells
• Purity/Purification: >90%, as determined by SDS-PAGE
• Form/Format: Recombinant Human EGFL7 was lyophilized from a 0.2 um filtered PBS solution pH 7.4.
• Sequence Length: 278

• Domain: EGF,EMI
• Host Note: DNA sequence encoding mature chain of Mouse EGFL7 (VE-Statin) isoform-1 to a C-terminal polyHis tag was expressed in Insect cells.
• Endotoxin: Endotoxin content was assayed using a LAL gel clot method.; Endotoxin level was found to be less than 0.1 ng/ug (1EU/ug).
• Reconstitution: A quick spin of the vial followed by reconstitution in distilled water to a concentration not less than 0.1 mg/mL. This solution can then be diluted into other buffers.
• Molecular Weight Note: Recombinant Mouse EGFL7 is a monomer consisting of 273 amino acid residue, and migrates as an approximately 33 kDa protein under reducing conditions in SDS-PAGE.
• Preparation and Storage: The lyophilized protein is stable for at least 2 years from date of receipt at -20 degree C.; Upon reconstitution, this cytokine can be stored in working aliquots at 2 degree - 8 degree C for one month, or at -20 degree C for six months, with a carrier protein without detectable loss of activity. ; ; Avoid repeated freeze/thaw cycles.

Related Product Information for EGFL recombinant protein

EGFL7 is an 30 kDa secreted protein that contain an Emilin-like (EMI) domain, and 2 epidermal growth factor (EGF) domains, one of which binds calcium. Based on these domains, it has been hypothesized that EGFL7 may self-assemble like extracellular matrix (ECM) proteins and, thus, could incorporate into ECM. EGFL7 has been reported to stimulate cell adhesion as well as motility in a manner similar to ECM proteins. EGFL7 has been shown to be primarily expressed by developing ECs but also by primordial germ cells and some central nervous system neurons. Interestingly, EGFL7 expression markedly decreases in ECs in postnatal life, but can be strongly up-regulated after various tissue injuries that lead to increased angiogenic responses.

Product Categories/Family for EGFL recombinant protein

Cytokines

References

• EGFL7: a unique angiogenic signaling factor in vascular development and disease .Blood, Dec 2011; 10.1182/blood-2011-10-322446.
• EGFL7 promotes tumor escape from immunity by repressing endothelial cell activation .Cancer Res., Dec 2011; 71: 7176 - 7186.
• gene expression profiling of placentae from women with early- and late-onset pre-eclampsia: down-regulation of the angiogenesis related genes acvrl1 and EGFL7 in early-onset disease .Mol. Hum. Reprod., Oct 2011; 10.1093/molehr/gar067.
• population pharmacokinetic (pk) analysis supports fixed dosing for the humanized monoclonal antibody (humab) anti-EGFL7 (megf0444a) administered intravenously in patients with advanced solid tumors. .ASCO Meeting Abstracts, May 2011; 29: 2586.
• a phase ib dose-escalation study of the safety, pharmacokinetics (pk), pharmacodynamics (pd), and antitumor activity of the humanized monoclonal antibody (humab) anti-EGFL7 (megf0444a) in combination with bevacizumab with or without paclitaxel in patients with advanced solid tumors. .ASCO Meeting Abstracts, May 2011; 29: 2514.